|
US6060503A
(en)
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
|
US5552412A
(en)
|
1995-01-09 |
1996-09-03 |
Pfizer Inc |
5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
|
|
UA51676C2
(uk)
|
1995-11-02 |
2002-12-16 |
Пфайзер Інк. |
(-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
|
|
IL120266A
(en)
|
1996-02-28 |
2005-05-17 |
Pfizer |
Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
|
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
|
US20040044080A1
(en)
|
1997-10-28 |
2004-03-04 |
Place Virgil A. |
Treatment of dyspareunia with topically administered nitroglycerin formulations
|
|
YU26700A
(sh)
|
1999-05-24 |
2002-06-19 |
Pfizer Products Inc. |
Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
|
|
EP1086692A3
(en)
|
1999-07-28 |
2003-07-09 |
Pfizer Products Inc. |
Estrogen agonists and antagonists for multiple indications
|
|
US6436977B1
(en)
|
1999-09-29 |
2002-08-20 |
Pfizer Inc. |
Dosing regimens for lasofoxifene
|
|
CO5271697A1
(es)
|
2000-01-12 |
2003-04-30 |
Pfizer Prod Inc |
Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
|
|
BR0108107A
(pt)
|
2000-01-28 |
2003-03-11 |
Endorech Inc |
Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
|
|
DE10039199A1
(de)
|
2000-08-10 |
2002-02-21 |
Schering Ag |
Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
|
|
JP2004507465A
(ja)
|
2000-08-11 |
2004-03-11 |
ワイス |
エストロゲン受容体陽性癌腫の治療方法
|
|
WO2002056903A2
(en)
|
2001-01-17 |
2002-07-25 |
Praecis Pharmaceuticals Inc. |
Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
|
|
AU781168B2
(en)
|
2001-01-26 |
2005-05-12 |
Pfizer Products Inc. |
Method of treating certain cancers using an estrogen agonist/antagonist
|
|
RU2278861C2
(ru)
|
2002-03-28 |
2006-06-27 |
Пфайзер Продактс Инк. |
Очищенный лазофоксифен и способ очистки рацемического лазофоксифена рекристаллизацией
|
|
PA8576201A1
(es)
|
2002-07-10 |
2004-05-26 |
Pfizer Prod Inc |
Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
|
|
US8835413B2
(en)
|
2004-10-20 |
2014-09-16 |
Endorecherche, Inc. |
Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
|
|
US20090012052A1
(en)
|
2006-11-09 |
2009-01-08 |
Ore Pharmaceuticals Inc. |
Method for treating er+ breast cancer
|
|
US20110015134A1
(en)
|
2007-04-16 |
2011-01-20 |
Retsky Michael W |
Method of treatment for early stage cancer
|
|
CZ2007373A3
(cs)
|
2007-05-29 |
2008-12-10 |
Zentiva, A. S |
Zpusob prípravy lasofoxifenu
|
|
CA2725390C
(en)
|
2008-04-08 |
2014-09-23 |
Syndax Pharmaceuticals, Inc. |
Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
|
|
WO2009137543A2
(en)
|
2008-05-06 |
2009-11-12 |
Ore Pharmaceuticals Inc. |
Methods for breast cancer screening and treatment
|
|
CN102405047B
(zh)
*
|
2009-01-30 |
2014-07-09 |
葛兰素史密斯克莱有限责任公司 |
结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐
|
|
EP2239570A1
(en)
|
2009-04-10 |
2010-10-13 |
PamGene B.V. |
Method for determining the estrogen receptor status of breast cancer
|
|
MX373926B
(es)
|
2009-05-27 |
2020-07-10 |
Ptc Therapeutics Inc |
Metodos para tratar cancer y estados no neoplasicos.
|
|
US20130253035A1
(en)
|
2010-08-16 |
2013-09-26 |
Duke University |
Camkk-beta as a target for treating cancer
|
|
US20120052508A1
(en)
|
2010-08-27 |
2012-03-01 |
Rutgers, The State University Of New Jersey |
Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
|
|
US20140134170A1
(en)
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
AU2012255920A1
(en)
|
2011-05-18 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Therapeutic anti-IGF1R combinations
|
|
WO2013056178A2
(en)
|
2011-10-14 |
2013-04-18 |
Foundation Medicine, Inc. |
Novel estrogen receptor mutations and uses thereof
|
|
EP2791128A4
(en)
|
2011-12-16 |
2015-04-22 |
Olema Pharmaceuticals Inc |
NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
|
|
US20160038506A1
(en)
|
2012-02-14 |
2016-02-11 |
Repros Therapeutics Inc. |
Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
|
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
|
US20160030389A1
(en)
|
2013-03-13 |
2016-02-04 |
Alevere Medical Corporation |
Use of indole compounds for fat reduction and skin and soft tissue tightening
|
|
US9204286B1
(en)
|
2013-03-15 |
2015-12-01 |
Sprint Communications Company L.P. |
System and method of branding and labeling a mobile device
|
|
WO2015136016A2
(en)
|
2014-03-13 |
2015-09-17 |
F. Hoffmann-La Roche Ag |
Therapeutic combinations with estrogen receptor modulators
|
|
SG11201607339VA
(en)
|
2014-03-13 |
2016-10-28 |
Hoffmann La Roche |
Methods and compositions for modulating estrogen receptor mutants
|
|
US9421264B2
(en)
|
2014-03-28 |
2016-08-23 |
Duke University |
Method of treating cancer using selective estrogen receptor modulators
|
|
ES3055185T3
(en)
|
2014-03-28 |
2026-02-10 |
Univ Duke |
Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
|
|
CN113101292B
(zh)
|
2014-05-08 |
2023-07-11 |
上海市生物医药技术研究院 |
双炔失碳酯组合物和疾病治疗方法
|
|
KR20170078811A
(ko)
|
2014-11-07 |
2017-07-07 |
리폭센 테크놀로지즈 리미티드 |
원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법
|
|
AU2016247674A1
(en)
|
2015-04-14 |
2017-10-19 |
Atossa Genetics Inc. |
Compositions and methods of treatment of breast disorders and estrogen-related disorders
|
|
KR20250152679A
(ko)
|
2015-04-29 |
2025-10-23 |
래디어스 파마슈티컬스, 인코포레이티드 |
암을 치료하는 방법
|
|
ES2909576T3
(es)
|
2016-10-11 |
2022-05-09 |
Univ Duke |
Tratamiento con lasofoxifeno del cáncer de mama ER+
|
|
WO2018071437A1
(en)
|
2016-10-11 |
2018-04-19 |
Sermonix Pharmaceuticals, Llc |
Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
|
|
CN115737637A
(zh)
|
2017-01-10 |
2023-03-07 |
王巍 |
拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
|
|
CN107861293A
(zh)
*
|
2017-12-21 |
2018-03-30 |
惠科股份有限公司 |
液晶显示器及其背光模组
|
|
US11497730B2
(en)
|
2018-04-10 |
2022-11-15 |
Duke University |
Lasofoxifene treatment of breast cancer
|
|
JP7571006B2
(ja)
|
2018-08-17 |
2024-10-22 |
ジェネンテック， インコーポレイテッド |
乳がんの処置のための診断的および治療的方法
|
|
EP4412649A4
(en)
|
2021-10-05 |
2025-11-05 |
Univ Duke |
Compositions containing small molecule tumor immunity regulators and their methods of use
|
|
GB202116903D0
(en)
|
2021-11-18 |
2022-01-05 |
Sermonix Pharmaceuticals Inc |
Lasofoxifene treatment of aromatase-resistant er+ cancer
|
|
JP2025517483A
(ja)
|
2022-05-25 |
2025-06-05 |
サーモニックス ファーマシューティカルズ， インコーポレイテッド |
Ｃｄｋ４／６阻害剤で進行したｅｒ＋乳がんのラソフォキシフェン併用処置
|